Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Decitabine 20 mg/m^2 Clear all
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

NCT00882102
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 4 Interventional Results available

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

NCT01011283
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
decitabine, azacitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Stanford, California • Stockton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

NCT00398983
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

NCT03063203
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult
Interventions
Decitabine, Bone marrow biopsy/aspirate, Peripheral blood draw, Skin biopsy, Buccal swab
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

NCT00075010
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Valproic acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

NCT01420926
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia
Interventions
Bortezomib, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
53
States / cities
Mountain View, California • Hartford, Connecticut • Lewes, Delaware + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

NCT00903760
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

NCT02348489
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
SGI-110 (guadecitabine), Treatment Choice
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
23
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

NCT00067808
View directory record Official record
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

NCT02996474
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Pembrolizumab, Decitabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

NCT02343939
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 1 Interventional

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT00941109
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

NCT02472145
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Decitabine 20 mg/m^2, Talacotuzumab 9 mg/kg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 3 Interventional

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

NCT03926624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

NCT00691938
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
LBH589, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 1 Interventional

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

NCT04172844
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Azacitidine, Venetoclax, Pevonedistat
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT00619099
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Canton, Ohio • Woonsocket, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 28, 2026, 6:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

NCT01498445
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT00414310
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Interventions
Decitabine, Valproic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

NCT00358644
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
60 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

NCT03941964
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Cancer
Interventions
Venetoclax, Azacitidine, Decitabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Tempe, Arizona • Denver, Colorado • Lone Tree, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

NCT02103478
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

NCT03306264
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
ASTX727, Dacogen
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 28, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

Trial of Decitabine in Patients With Acute Myeloid Leukemia

NCT00260832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine or Supportive Care, Dacogen (decitabine) only
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
65 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
37
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 28, 2026, 6:22 PM EDT